Novo Nordisk Partners with Anthropic to Deploy Claude AI in R&D

Danish drugmaker Novo Nordisk and Anthropic announced a partnership on Wednesday to accelerate the discovery and development of new medicines. [1] The collaboration will involve Novo Nordisk utilizing the AI company's Claude models to speed up its drug development processes. [1]

As part of the initial phase, Novo Nordisk plans to test Anthropic models in its research and development workflows. [1] The drugmaker will specifically test Claude Science to help address scientific problems. [1] Novo Nordisk is the maker of the drug Wegovy. [3]

The alliance between Novo Nordisk and Anthropic highlights a targeted integration of generative AI into pharmaceutical research. By bringing Claude models, including Claude Science, directly into its workflows, the maker of Wegovy is positioning itself to accelerate complex drug discovery pipelines. This move underscores a broader reliance on specialized AI assistants for scientific problem-solving rather than general-purpose tasks. What the sources don't address: How much financial investment is involved in the partnership or when the initial testing phase of Claude Science will be completed.